PMID- 33827387
OWN - NLM
STAT- MEDLINE
DCOM- 20210924
LR  - 20210924
IS  - 1793-6853 (Electronic)
IS  - 0192-415X (Linking)
VI  - 49
IP  - 4
DP  - 2021
TI  - 4-Acetylantrocamol LT3 Inhibits Glioblastoma Cell Growth and Downregulates DNA 
      Repair Enzyme O(6)-Methylguanine-DNA Methyltransferase.
PG  - 983-999
LID - 10.1142/S0192415X21500476 [doi]
AB  - Glioblastoma multiforme (GBM) is a deadly malignant brain tumor that is resistant 
      to most clinical treatments. Novel therapeutic agents that are effective against 
      GBM are required. Antrodia cinnamomea has shown antiproliferative effects in GBM 
      cells. However, the exact mechanisms and bioactive components remain unclear. 
      Thus, the present study aimed to investigate the effect and mechanism of 
      4-acetylantrocamol LT3 (4AALT3), a new ubiquinone from Antrodia 
      cinnamomeamycelium, in vitro. U87 and U251 cell lines were treated with the 
      indicated concentration of 4AALT3. Cell viability, cell colony-forming ability, 
      migration, and the expression of proteins in well-known signaling pathways 
      involved in the malignant properties of glioblastoma were then analyzed by CCK-8, 
      colony formation, wound healing, and western blotting assays, respectively. We 
      found that 4AALT3 significantly decreased cell viability, colony formation, and 
      cell migration in both in vitro models. The epidermal growth factor receptor 
      (EGFR), phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin 
      (mTOR), Hippo/yes-associated protein (YAP), and cAMP-response element binding 
      protein (CREB) pathways were suppressed by 4AALT3. Moreover, 4AALT3 decreased the 
      level of DNA repair enzyme O(6)-methylguanine-DNA methyltransferase and showed a 
      synergistic effect with temozolomide. Our findings provide the basis for 
      exploring the beneficial effect of 4AALT3 on GBM in vivo.
FAU - Lee, Shih-Yu
AU  - Lee SY
AD  - Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical 
      Center, Taipei, Taiwan.
FAU - Yen, I-Chuan
AU  - Yen IC
AD  - School of Pharmacy, National Defense Medical Center, Taipei, Taiwan.
FAU - Lin, Jang-Chun
AU  - Lin JC
AD  - Department of Radiation Oncology, Shuang Ho Hospital, Taipei Medical University, 
      Taipei, Taiwan.
AD  - Department of Radiology, School of Medicine, College of Medicine, Taipei Medical 
      University, Taipei, Taiwan.
FAU - Chung, Min-Chieh
AU  - Chung MC
AD  - Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical 
      Center, Taipei, Taiwan.
FAU - Liu, Wei-Hsiu
AU  - Liu WH
AD  - Department of Surgery, School of Medicine, National Defense Medical Center, 
      Taipei, Taiwan.
AD  - Department of Neurological Surgery Tri-Service General Hospital and National 
      Defense Medical Center, No. 325, Sec. 2 Cheng-Kung Road Taipei 11490, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20210406
PL  - Singapore
TA  - Am J Chin Med
JT  - The American journal of Chinese medicine
JID - 7901431
RN  - 0 (Cyclohexanones)
RN  - 1339-63-5 (Ubiquinone)
RN  - 5Z93L87A1R (Guanine)
RN  - 72XZO87CZJ (4-acetylantroquinonol B)
RN  - 9B710FV2AE (O-(6)-methylguanine)
RN  - EC 2.1.1.37 (DNA (Cytosine-5-)-Methyltransferase 1)
RN  - EC 2.1.1.37 (DNMT1 protein, human)
RN  - OL659KIY4X (4-Butyrolactone)
SB  - IM
MH  - 4-Butyrolactone/*analogs & derivatives/chemistry/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Cyclohexanones/chemistry/*pharmacology
MH  - DNA (Cytosine-5-)-Methyltransferase 1/*metabolism
MH  - DNA Repair/*drug effects
MH  - Down-Regulation
MH  - Glioblastoma/*drug therapy
MH  - Guanine/*analogs & derivatives/metabolism
MH  - Humans
MH  - Ubiquinone/pharmacology
OTO - NOTNLM
OT  - 4-Acetylantrocamol LT3
OT  - CREB
OT  - Glioblastoma Multiforme
OT  - MGMT
OT  - YAP
OT  - mTOR
EDAT- 2021/04/09 06:00
MHDA- 2021/09/25 06:00
CRDT- 2021/04/08 05:31
PHST- 2021/04/09 06:00 [pubmed]
PHST- 2021/09/25 06:00 [medline]
PHST- 2021/04/08 05:31 [entrez]
AID - 10.1142/S0192415X21500476 [doi]
PST - ppublish
SO  - Am J Chin Med. 2021;49(4):983-999. doi: 10.1142/S0192415X21500476. Epub 2021 Apr 
      6.